Gyre Therapeutics, Inc. reported a board expansion and committee appointments following action by its board of directors on July 10, 2026. The company appointed three new directors, each to a different director class, with all appointments becoming effective August 1, 2026. Yue Xiong, Ph.D. was appointed as a Class I director. Dr. Xiong already serves as Gyre’s Chief Scientific Officer, and the company said he will receive no additional compensation for his board service. He had previously entered into Gyre’s standard indemnification agreement in connection with his executive appointment. The board also appointed Maxwell Kirkby as a Class II director and Claire Weston, Ph.D. as a Class III director. In addition to joining the board, Kirkby was appointed to serve on the board’s Compensation Committee, while Weston was appointed to serve on the Audit Committee. Gyre disclosed compensation arrangements for the two non-employee appointees. Kirkby and Weston will each receive an initial stock option grant to purchase 40,000 shares of Gyre common stock. The options will vest in equal monthly installments over three years. They will also receive cash compensation under the company’s non-employee director compensation policy, as described in Gyre’s definitive proxy statement filed April 27, 2026. The filing did not disclose the exercise price of the option grants. Kirkby and Weston will also enter into Gyre’s standard form of indemnification agreement. The company stated that none of the three appointees was selected pursuant to any arrangement or understanding with another person, that there are no family relationships between the appointees and any Gyre director or executive officer, and that none of them is involved in a related-party transaction requiring disclosure under Item 404(a) of Regulation S-K. The Form 8-K was filed under Item 5.02, covering director appointments and compensatory arrangements, and also included Item 7.01 Regulation FD disclosure to furnish the company’s July 16, 2026 press release announcing the appointments.